All In Biotech

Free tool

FAERS Monitor: Axumin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208054 or its brand name (Axumin, Fluciclovine F-18). Reports on generic versions are filed under their own applications.

Reports

102

Serious

5

5% of reports

Hospitalization

2

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • positron emission tomogram abnormal22
  • no adverse event18
  • therapeutic response unexpected18
  • scan abnormal11
  • off label use8
  • false negative investigation result7
  • drug ineffective6
  • injection site extravasation5
  • false positive investigation result4
  • therapeutic product effect decreased4
  • diarrhoea3
  • extravasation2
  • malaise2
  • manufacturing product shipping issue2
  • product dose omission2

Reports by year received

View as table
YearReports
20171
201814
201914
20201
20211
202230
20238
20244
202526
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,057 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
positron emission tomogram abnormalSignal226707.64597.8136,464
scan abnormalSignal116342.33594.961,653
false negative investigation resultSignal72076.01011.712,393
false positive investigation resultSignal4820.7313.42,497
manufacturing product shipping issue2763.1193.0852
extravasation2100.425.4110
injection site extravasationSignal583.635.6330
therapeutic response unexpectedSignal1882.854.41,376
no adverse eventSignal1820.513.5317
therapeutic product effect decreasedSignal418.47.050
product dose omission26.31.64
off label use81.91.03
diarrhoea31.00.30
malaise20.90.20
drug ineffective60.90.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.